National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England

Estimated value

goods

Awarded value

Suppliers

93

24 SME

Lots

49

93 awarded

Published

28 Apr 2021

Description

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. Period of framework agreement: 1 April 2021 to 31 March 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Scope

Reference
ocds-h6vhtk-02ab4a
Commercial tool
Standalone contract
Main category
goods
CPV classifications
33600000
Contract locations
UK

Award criteria

Criteria the buyer will use to evaluate bids.

NameDescriptionTypeWeighting
price

Submission & procedure

Procedure
Open procedure

Award details· 93 awards

Awarded supplier(s), contract period and value as published in the award notice.

Awarded value

Award date

Contract start

Contract end

Awarded to

Lots · 49 total

Divisions of the contract. Each lot can be awarded separately.

View all →
LotTitleEst. valueStatus
25Fluorouracil in Elastomeric Devices (Autofuser 2ml/hr) - Lot 25cancelled
22Fluorouracil in Elastomeric Devices (Folfusor LV1.5) - Lot 22cancelled
1Atezolizumab - Lot 1 cancelled
2Bevacizumab (Avastin) - Lot 2cancelled
3Bevacizumab (Zirabev) - Lot 3 cancelled